Karyopharm Therapeutics Inc (FRA:25K)
€ 0.5734 -0.0194 (-3.27%) Market Cap: 84.88 Mil Enterprise Value: 143.15 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 64/100

Karyopharm Therapeutics Inc at Morgan Stanley Global Healthcare Conference Transcript

Sep 12, 2022 / 04:30PM GMT
Release Date Price: €5.28 (-0.32%)
Michael Eric Ulz
Morgan Stanley, Research Division - Equity Analyst

All right. Good afternoon, everyone, and thanks for joining us at the Morgan Stanley Global Healthcare Conference. I'm Mike Ulz, one of the biotech analysts here, and it's my pleasure to introduce the team from Karyopharm Therapeutics, including Richard Paulson, CEO, on my far left; and Reshma Rangwala, CMO, on my near left.

Just a reminder, the format for today is a fireside chat. But before we get started, I just need to read a quick disclaimer. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. And if you have any questions, please reach out to your Morgan Stanley sales representative. And with that, we can start the Q&A.

Questions & Answers

Michael Eric Ulz
Morgan Stanley, Research Division - Equity Analyst

So I thought maybe, obviously, XPOVIO is an important part of the story here. It's been on

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot